Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

59.34 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Jul 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

91 92 Next >

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

July 13, 2026

From Bristol Myers Squibb

Via Business Wire

2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

July 07, 2026

They may not remain cheap for too much longer.

Via The Motley Fool

Topics Intellectual Property

3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List) ↗

July 07, 2026

It doesn't get much more dependable and lucrative than the healthcare industry.

Via The Motley Fool

Topics Intellectual Property

Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Play with Cautionary Notes ↗

June 26, 2026

Via Chartmill

Bristol-Myers Squibb Co (NYSE:BMY): High Yield and Solid Profitability, but Growth Concerns Loom ↗

June 05, 2026

Via Chartmill

Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know. ↗

July 06, 2026

This big pharma stock looks attractive for income investors -- but it comes with some risk.

Via The Motley Fool

Topics Intellectual Property

Vanguard Is Bullish on Value Stocks and Fixed Income. Are These 2 ETFs a Good Buy? ↗

July 05, 2026

Strong productivity gains from AI -- and lower inflation -- could be good news for these Vanguard ETFs.

Via The Motley Fool

Topics Artificial Intelligence Bonds ETFs

2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds

July 03, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 01, 2026

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?

Via The Motley Fool

Rolling Into Spreads: Extend Profit Potential with Lower Risk ↗

June 30, 2026

Learn how a vertical spread options strategy can help reduce risk, lock in gains, and stay invested in winning trades.

Via InvestorPlace

June 30, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 26, 2026

Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.

Via The Motley Fool

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

June 24, 2026

Via Investor Brand Network

The Quest to Repair What Multiple Sclerosis Takes Away

June 24, 2026

From BioMedWire

Via GlobeNewswire

3 Reasons to Buy Bristol Myers Squibb Stock ↗

June 22, 2026

Fears about a looming patent cliff have dragged on the shares.

Via The Motley Fool

Topics Intellectual Property

1 S&P 500 Stock with Solid Fundamentals and 2 We Avoid

June 22, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

Via StockStory

Topics Stocks

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

June 18, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Dividend

June 17, 2026

From Bristol Myers Squibb

Via Business Wire

3 Dividend Stocks to Hold for the Long Haul ↗

June 16, 2026

They have a habit of consistently raising their payouts.

Via The Motley Fool

Topics Intellectual Property

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. ↗

June 13, 2026

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.

Via The Motley Fool

Topics Bonds Intellectual Property

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. ↗

June 11, 2026

"Productivity initiatives" could prove key in maintaining this pharma company's decades-long dividend growth streak.

Via The Motley Fool

Topics Intellectual Property

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

June 08, 2026

From Bristol Myers Squibb

Via Business Wire

Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗

June 08, 2026

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

Via The Motley Fool

Topics Intellectual Property Stocks

Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock ↗

June 05, 2026

What does this smart money investor see that the market is missing?

Via The Motley Fool

Topics Intellectual Property

Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? ↗

June 04, 2026

Durability, not yield, is the deciding factor.

Via The Motley Fool

3 Value Stocks We Think Twice About

June 04, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗

June 03, 2026

Whichever one you choose, you'll need patience before you can see solid returns.

Via The Motley Fool

Topics Intellectual Property

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

June 02, 2026

From Bristol Myers Squibb

Via Business Wire

Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗

June 01, 2026

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

Via The Motley Fool

Topics Intellectual Property

Explore the top gainers and losers within the S&P500 index in today's session. ↗

June 01, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

91 92 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.